MarginsXMarginsX
Home › Markets › Health Care › AAPG

Ascentage Pharma Group International American Depository Shares (AAPG)

AAPG trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$13.29
-9.10% on the day
Market cap
$1.2B
Small cap
Revenue · 2025
$86.1M
-35.9% on 2024
Net income · 2025
-$186.3M
-216.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2023311/000121390026049412/0001213900-26-049412-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from CNY at 6.6719 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerAAPG on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryChina
IPO year2025
SEC CIK0002023311
SEC industry codePharmaceutical Preparations
Incorporated inCayman Islands

Financials · 2025

LineValue
Revenue$86.1M
Net income-$186.3M
Operating incomeNot in SEC XBRL data
Net margin-216.5%
Operating marginOperating income not reported
Revenue growth-35.9%
Cash$179.2M
Total assetsNot in SEC XBRL data
P/E (computed)Net income was not positive
P/S (computed)14.4×

Reported in CNY; shown in US dollars.

Warning signs

Cash runway
12.2 months
$179.2M cash at December 31, 2025
Share count, 1 year
+7.2%
2025-03-01 to 2026-04-01
Going-concern doubt
No
20-F filed April 29, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-29
Cash and burn$179.2M cash; operating cash flow -$44.0M a quarter.Report 2025-12-31
Shares outstanding93,330,548 (2026-04-01); 87,066,645 a year earlier. the newest SEC cover-page count is from 2026-04-01; shares issued since then are not in these figures.Cover page 2026-04-01
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-07-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young Hua Ming LLP, Shanghai, ChinaPCAOB Form AP 2026-05-21
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$86.1M-$186.3M-$176.0M$179.2M$296.7M$86.1M20-F 2026-04-29
FY 2024
2024-12-31
$134.3M-$55.5M-$15.3M$122.4M$228.6M$134.3M20-F 2025-04-16

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42025-01-24
Latest annual report
ANNUAL REPORT
20-F2026-04-29
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-16

Source: SEC EDGAR submissions feed, 134 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.2%
1 month-2.9%
3 months-23.1%
Year to date-44.3%
1 year-56.6%
From 52-week high-57.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AMPHAmphastar Pharmaceuticals Inc.$29.17-0.68%$1.2B
NKTRNektar Therapeutics$36.44-2.23%$1.2B
SLNSilence Therapeutics Plc American Depository Share$19.80-0.15%$1.2B
MNKDMannKind Corporation$3.96-4.24%$1.3B
OMEROmeros Corporation$16.68-4.63%$1.2B
OPKOPKO Health Inc.$1.62-3.57%$1.2B
KARDKardigan Inc.$12.85-7.02%$1.2B
GHRSGH Research PLC$18.75-1.83%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier